STOCK TITAN

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NewAmsterdam Pharma (Nasdaq: NAMS) has announced its participation in two major conferences this November. The company will present new safety and efficacy data from their Phase 3 BROOKLYN study of obicetrapib at the 2024 American Heart Association Scientific Sessions in Chicago (November 16-18). The study focuses on patients with Heterozygous Familial Hypercholesterolemia.

Additionally, the company's management will participate in the Jefferies London Healthcare Conference (November 19-21). Dr. Stephen Nicholls will present the BROOKLYN study findings on November 18, while CEO Michael Davidson, CSO John Kastelein, and CFO Ian Somaiya will lead a fireside chat on November 21. A live webcast of the Jefferies presentation will be available on the company's investor relations website.

NewAmsterdam Pharma (Nasdaq: NAMS) ha annunciato la sua partecipazione a due importanti conferenze questo novembre. L'azienda presenterà nuovi dati sulla sicurezza e l'efficacia del loro studio BROOKLYN di Fase 3 relativo all'obicetrapib durante le 2024 American Heart Association Scientific Sessions a Chicago (16-18 novembre). Lo studio si concentra su pazienti con ipercolesterolemia familiare eterozigote.

Inoltre, il management dell'azienda parteciperà alla Jefferies London Healthcare Conference (19-21 novembre). Il Dr. Stephen Nicholls presenterà i risultati dello studio BROOKLYN il 18 novembre, mentre il CEO Michael Davidson, il CSO John Kastelein e il CFO Ian Somaiya guideranno una chiacchierata informale il 21 novembre. Una trasmissione in diretta della presentazione di Jefferies sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda.

NewAmsterdam Pharma (Nasdaq: NAMS) ha anunciado su participación en dos importantes conferencias este noviembre. La empresa presentará nuevos datos de seguridad y eficacia de su estudio BROOKLYN de Fase 3 sobre obicetrapib en las 2024 American Heart Association Scientific Sessions en Chicago (16-18 de noviembre). El estudio se centra en pacientes con hiperlipidemia familiar heterocigota.

Además, la dirección de la empresa participará en la Jefferies London Healthcare Conference (19-21 de noviembre). El Dr. Stephen Nicholls presentará los hallazgos del estudio BROOKLYN el 18 de noviembre, mientras que el CEO Michael Davidson, el CSO John Kastelein y el CFO Ian Somaiya dirigirán una charla informal el 21 de noviembre. Una retransmisión en vivo de la presentación de Jefferies estará disponible en el sitio web de relaciones con inversores de la empresa.

뉴암스테르담 제약 (Nasdaq: NAMS)가 이번 11월에 두 개의 주요 컨퍼런스에 참여할 것임을 발표했습니다. 이 회사는 제3상 브루클린 연구에서의 오비세트라피브에 대한 새로운 안전성 및 효능 데이터를 가면적인 2024 미국심장협회 과학 세션에서 시카고(11월 16-18일)에서 발표할 예정입니다. 이 연구는 이형접합 가족성 고콜레스테롤혈증 환자에 초점을 맞추고 있습니다.

또한, 회사 경영진은 제퍼리즈 런던 헬스케어 컨퍼런스 (11월 19-21일)에 참여합니다. Stephen Nicholls 박사는 11월 18일 브루클린 연구 결과를 발표할 예정이며, CEO Michael Davidson, CSO John Kastelein 및 CFO Ian Somaiya가 11월 21일에 비공식적인 대화를 진행할 것입니다. 제퍼리즈 발표의 생중계는 회사의 투자자 관계 웹사이트에서 제공될 예정입니다.

NewAmsterdam Pharma (Nasdaq: NAMS) a annoncé sa participation à deux grandes conférences en novembre. L'entreprise présentera de nouvelles données sur la sécurité et l'efficacité de son étude BROOKLYN de Phase 3 concernant l'obicetrapib lors des 2024 American Heart Association Scientific Sessions à Chicago (16-18 novembre). L'étude se concentre sur les patients atteints d'hypercholestérolémie familiale hétérozygote.

De plus, la direction de l'entreprise participera à la Jefferies London Healthcare Conference (19-21 novembre). Le Dr Stephen Nicholls présentera les résultats de l'étude BROOKLYN le 18 novembre, tandis que le PDG Michael Davidson, le CSO John Kastelein et le CFO Ian Somaiya animeront une discussion informelle le 21 novembre. Une diffusion en direct de la présentation de Jefferies sera disponible sur le site web des relations avec les investisseurs de l'entreprise.

NewAmsterdam Pharma (Nasdaq: NAMS) hat seine Teilnahme an zwei wichtigen Konferenzen im November angekündigt. Das Unternehmen wird neue Sicherheits- und Wirksamkeitsdaten aus der Phase 3 BROOKLYN-Studie zu Obicetrapib bei den 2024 American Heart Association Scientific Sessions in Chicago (16.-18. November) präsentieren. Die Studie konzentriert sich auf Patienten mit heterozygoter familiärer Hypercholesterinämie.

Darüber hinaus wird das Management des Unternehmens an der Jefferies London Healthcare Conference (19.-21. November) teilnehmen. Dr. Stephen Nicholls wird am 18. November die Ergebnisse der BROOKLYN-Studie präsentieren, während CEO Michael Davidson, CSO John Kastelein und CFO Ian Somaiya am 21. November ein informelles Gespräch führen werden. Eine Live-Übertragung der Jefferies-Präsentation wird auf der Investor-Relations-Website des Unternehmens verfügbar sein.

Positive
  • None.
Negative
  • None.

NAARDEN, The Netherlands and MIAMI, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional safety and efficacy data from the pivotal Phase 3 BROOKLYN study evaluating obicetrapib in patients with Heterozygous Familial Hypercholesterolemia in a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions, taking place November 16 – 18, 2024 in Chicago, Illinois. Additionally, NewAmsterdam announced that company management will participate in the Jefferies London Healthcare Conference, taking place November 19 – 21, 2024 in London. Details are as follows:

2024 AHA Scientific Sessions

Presentation Title: Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia (BROOKLYN)
Session Title: Late-Breaking Science 8: New Targets and New Treatments: Advances in Lipid Therapeutics
Presentation Date and Time: Monday, November 18, 2024, 2:14 p.m. – 2:26 p.m. CST (3:14 p.m. – 3:26 p.m. ET)
Presenter: Stephen Nicholls, M.B.B.S., Ph.D., Director, Monash Victorian Heart Institute and Professor of Cardiology, Monash University

Jefferies London Healthcare Conference

Fireside Chat Date and Time: Thursday, November 21, 2024, at 1:00pm GMT
Presenters: Michael Davidson, M.D., Chief Executive Officer, NewAmsterdam Pharma, John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, Ian Somaiya, Chief Financial Officer

A live webcast of the Jefferies fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.

About Obicetrapib

Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN trial, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company is conducting an additional Phase 3 pivotal trial BROADWAY, to evaluate obicetrapib as a monotherapy used as an adjunct to maximally tolerated lipid-lowering therapies to provide additional LDL-lowering for CVD patients, and TANDEM, to evaluate obicetrapib and ezetimibe as a fixed-dose combination. The Company began enrolling patients in BROADWAY in January 2022 and in TANDEM in March 2024; completing enrollment of BROADWAY in July 2023, and TANDEM in July 2024. The Company also commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and non-elective coronary revascularization. NewAmsterdam completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed dose combination with ezetimibe, for cardiovascular diseases have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact

Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact

Spectrum Science on behalf of NewAmsterdam
Bryan Blatstein
P: 1-917-714-2609
bblatstein@spectrumscience.com

Investor Contact

Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com


FAQ

When will NewAmsterdam Pharma (NAMS) present the BROOKLYN study results at AHA 2024?

NewAmsterdam Pharma will present the BROOKLYN study results on Monday, November 18, 2024, from 2:14 p.m. to 2:26 p.m. CST at the AHA Scientific Sessions in Chicago.

What is the focus of NewAmsterdam Pharma's BROOKLYN study presentation at AHA 2024?

The presentation will focus on the safety and efficacy data of obicetrapib in patients with Heterozygous Familial Hypercholesterolemia from the Phase 3 BROOKLYN study.

When is NewAmsterdam Pharma's (NAMS) presentation at the Jefferies London Healthcare Conference?

NewAmsterdam Pharma will participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 1:00pm GMT.

Where can investors watch NewAmsterdam Pharma's Jefferies Conference presentation?

Investors can watch the live webcast through the investor relations section of NewAmsterdam Pharma's website at ir.newamsterdampharma.com, where an archived replay will also be available afterward.

NewAmsterdam Pharma Company N.V. Ordinary Shares

NASDAQ:NAMS

NAMS Rankings

NAMS Latest News

NAMS Stock Data

1.89B
79.29M
0.25%
89.54%
0.78%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NARRDEN